EOE1
MCID: ESP035
MIFTS: 57

Esophagitis, Eosinophilic, 1 (EOE1)

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Esophagitis, Eosinophilic, 1

MalaCards integrated aliases for Esophagitis, Eosinophilic, 1:

Name: Esophagitis, Eosinophilic, 1 57 13
Eosinophilic Esophagitis 12 58 36 42 44 15 17 70
Esophagitis, Eosinophilic; Ee 57
Esophagitis, Eosinophilic 57
Eoe1 57
Eoe 58
Ee 57

Characteristics:

Orphanet epidemiological data:

58
eosinophilic esophagitis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Canada),1-5/10000 (Japan),1-5/10000 (Spain),1-5/10000 (Europe),1-5/10000 (United States),1-9/100000 (Switzerland),1-5/10000 (Switzerland); Age of onset: All ages; Age of death: normal life expectancy;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
multifactorial

Miscellaneous:
predominantly occurs in young males with high rate of atopic disease


Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:13922
OMIM® 57 610247
KEGG 36 H01361
ICD9CM 34 530.13
MeSH 44 D057765
NCIt 50 C27105
SNOMED-CT 67 235599003
ICD10 32 K20.0
MESH via Orphanet 45 D057765
ICD10 via Orphanet 33 K20
UMLS via Orphanet 71 C0341106
Orphanet 58 ORPHA73247
MedGen 41 C4551589
UMLS 70 C0341106

Summaries for Esophagitis, Eosinophilic, 1

MedlinePlus : 42 What is eosinophilic esophagitis (EoE)? Eosinophilic esophagitis (EoE) is a chronic disease of the esophagus. Your esophagus is the muscular tube that carries food and liquids from your mouth to the stomach. If you have EoE, white blood cells called eosinophils build up in your esophagus. This causes damage and inflammation, which can cause pain and may lead to trouble swallowing and food getting stuck in your throat. EoE is rare. But because it is a newly recognized disease, more people are now getting diagnosed with it. Some people who think that they have reflux (GERD) may actually have EoE. What causes eosinophilic esophagitis (EoE)? Researchers are not certain about the exact cause of EoE. They think that it is an immune system/allergic reaction to foods or to substances in your environment, such as dust mites, animal dander, pollen, and molds. Certain genes may also play a role in EoE. Who is at risk for eosinophilic esophagitis(EoE)? EoE can affect anyone, but it is more common in people who Are male Are white Have other allergic diseases, such as hay fever, eczema, asthma and food allergies Have family members with EoE What are the symptoms of eosinophilic esophagitis (EoE)? The most common symptoms of EoE can depend on your age. In infants and toddlers: Feeding problems Vomiting Poor weight gain and growth Reflux that does not get better with medicines In older children: Vomiting Abdominal pain Trouble swallowing, especially with solid foods Reflux that does not get better with medicines Poor appetite In adults: Trouble swallowing, especially with solid foods Food getting stuck in the esophagus Reflux that does not get better with medicines Heartburn Chest pain How is eosinophilic esophagitis (EoE) diagnosed? To diagnose EoE, your doctor will Ask about your symptoms and medical history. Since other conditions can have the same symptoms of EoE, it is important for your doctor to take a thorough history. Do an upper gastrointestinal (GI) endoscopy. An endoscope is a long, flexible tube with a light and camera at the end of it. Your doctor will run the endoscope down your esophagus and look at it. Some signs that you might have EoE include white spots, rings, narrowing, and inflammation in the esophagus. However, not everyone with EoE has those signs, and sometimes they can be signs of a different esophagus disorder. Do a biopsy. During the endoscopy, the doctor will take small tissue samples from your esophagus. The samples will be checked for a high number of eosinophils. This is the only way to make a diagnosis of EoE. Do other tests as needed. You may have blood tests to check for other conditions. If you do have EoE, you may have blood or other types of tests to check for specific allergies. What are the treatments for eosinophilic esophagitis (EoE)? There is no cure for EoE. Treatments can manage your symptoms and prevent further damage. The two main types of treatments are medicines and diet. Medicines used to treat EoE are Steroids, which can help control inflammation. These are usually topical steroids, which you swallow either from an inhaler or as a liquid. Sometimes doctors prescribe oral steroids (pills) to treat people who have serious swallowing problems or weight loss. Acid suppressors such as proton pump inhibitors (PPIs), which may help with reflux symptoms and decrease inflammation. Dietary changes for EoE include Elimination diet. If you are on an elimination diet, you stop eating and drinking certain foods and beverages for several weeks. If you are feeling better, you add the foods back to your diet one at a time. You have repeat endoscopies to see whether or not you are tolerating those foods. There are different types of elimination diets: With one type, you first have an allergy test. Then you stop eating and drinking the foods you are allergic to. For another type, you eliminate foods and drinks that commonly cause allergies, such as dairy products, egg, wheat, soy, peanuts, tree nuts and fish/shellfish. Elemental diet. With this diet, you stop eating and drinking all proteins. Instead, you drink an amino acid formula. Some people who do not like the taste of the formula use a feeding tube instead. If your symptoms and inflammation go away completely, you may be able to try adding foods back one at a time, to see whether you can tolerate them. Which treatment your health care provider suggests depends on different factors, including your age. Some people may use more than one kind of treatment. Researchers are still trying to understand EoE and how best to treat it. If your treatment is not working well enough and you have narrowing of the esophagus, you may need dilation. This is a procedure to stretch the esophagus. This makes it easier for you to swallow.

MalaCards based summary : Esophagitis, Eosinophilic, 1, also known as eosinophilic esophagitis, is related to ige responsiveness, atopic and gastroesophageal reflux, and has symptoms including vomiting and epigastric pain. An important gene associated with Esophagitis, Eosinophilic, 1 is BANCR (BRAF-Activated Non-Protein Coding RNA), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs Fluticasone and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include esophagus, skin and lung, and related phenotypes are dysphagia and edema

Disease Ontology : 12 An esophagitis characterized by inflammation involving eosinophils located in esophagus.

OMIM® : 57 Eosinophilic esophagitis (EOE) has an incidence of approximately 1 per 10,000 people. Symptoms include difficulty feeding, failure to thrive, vomiting, epigastric or chest pain, dysphagia, and food impaction. Individuals with EOE are predominantly young males with a high rate of atopic disease, and the diagnosis is made by endoscopy and biopsy findings of isolated eosinophils in the esophagus (summary by Rothenberg et al., 2010). (610247) (Updated 20-May-2021)

KEGG : 36 Eosinophilic esophagitis (EoE) is a chronic immune and antigen-mediated clinicopathologic disease that is characterized by eosinophil infiltration into the esophageal epithelium and results in esophageal fibrosis and dysfunction. Several factors contribute to the development of EoE, including genetic predisposition, history of allergies, and presence of environmental and food allergens. Recently, an association between a single nuclear polymorphism (SNP) in the gene encoding thymic stromal lymphopoietin (TSLP) or eotaxin-3 (CCL-26) and risk for EoE was found.

Wikipedia : 73 Eosinophilic esophagitis (EoE) is an allergic inflammatory condition of the esophagus that involves... more...

Related Diseases for Esophagitis, Eosinophilic, 1

Diseases in the Esophagitis, Eosinophilic, 1 family:

Esophagitis, Eosinophilic, 2

Diseases related to Esophagitis, Eosinophilic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 406)
# Related Disease Score Top Affiliating Genes
1 ige responsiveness, atopic 31.9 IL5 IL4 IL13
2 gastroesophageal reflux 31.7 IL5 IL4 CCR3 CCL26 CCL11 ATP4A
3 esophageal disease 31.7 CCR6 CCL26 ATP4A ATP12A
4 peptic esophagitis 31.6 CCL26 ATP4A ATP12A
5 food allergy 31.6 IL5 IL4 IL13 FLG EPX
6 esophageal candidiasis 31.3 CCR6 CCL26 ATP4A ATP12A
7 rhinitis 31.2 TSLP IL5 IL4 IL13 EPX CCL11
8 cytokine deficiency 31.2 IL5 IL13
9 celiac disease 1 31.2 IL5 IL4 IL13 CCR6 ATP4A ATP12A
10 allergic rhinitis 31.0 IL5 IL4 IL13 EPX CCR3 CCL24
11 dyskinesia of esophagus 31.0 IL13 CCL26 CAPN14 ATP4A ATP12A
12 pollen allergy 31.0 IL5 IL13 EPX
13 dermatitis 30.9 TSLP IL5 IL4 IL13 FLG CCR6
14 milk allergy 30.9 IL5 IL4 IL13
15 drug allergy 30.7 IL5 IL13 ATP4A ATP12A
16 hernia, hiatus 30.7 ATP4A ATP12A
17 allergic disease 30.6 TSLP RNASE2 IL5 IL4 IL13 EPX
18 inflammatory bowel disease 30.6 IL5 IL4 IL13 EPX CCR6 CCL11
19 peanut allergy 30.6 IL5 IL4 IL13 FLG CCR6
20 ulcerative colitis 30.5 IL4 IL13 CCR6 CCR3
21 gastric dilatation 30.5 ATP4A ATP12A
22 mediastinitis 30.5 ATP4A ATP12A
23 volvulus of midgut 30.5 IL5 ATP4A ATP12A
24 intrinsic asthma 30.5 IL5 IL4 IL13 CCL24
25 dermatitis, atopic 30.4 TSLP PTGDR2 IL5 IL4 IL13 FLG
26 microscopic colitis 30.4 IL4 ATP4A ATP12A
27 autoimmune gastritis 30.4 IL4 CCR6 ATP4A
28 respiratory allergy 30.4 TSLP IL5 IL4 IL13 CCR6
29 allergic asthma 30.4 TSLP IL5 IL4 IL13 EPX CCL26
30 chronic urticaria 30.3 PTGDR2 IL4 IL13
31 aspergillosis 30.3 IL5 IL4 EPX CCR6
32 colitis 30.2 IL4 IL13 CCR6 CCR3
33 alopecia areata 30.2 IL4 IL13 FLG
34 diphtheria 30.2 IL5 IL4 IL13
35 skin disease 30.2 TSLP IL5 IL4 IL13 FLG CCR6
36 immune deficiency disease 30.2 IL4 IL13 CCR6 CCR3 CCL11
37 gastroenteritis 30.2 TSLP IL5 IL4 EPX CCL11
38 bronchitis 30.1 IL5 IL4 IL13 CCR3 CCL11
39 egg allergy 30.0 TSLP IL5 IL4 IL13 FLG CCR6
40 eosinophilic gastroenteritis 29.8 TSLP IL5 IL4 EPX CCR6 CCL26
41 eosinophilic gastritis 29.7 SIGLEC8 RNASE2 IL5 IL13 EPX CCL26
42 hypereosinophilic syndrome 29.7 IL5 IL4 IL13 EPX CCR3 CCL26
43 asthma 29.6 TSLP RNASE2 PTGDR2 IL5 IL4 IL13
44 esophagitis 29.4 TSLP IL5 IL4 IL13 FLG CCR3
45 esophagitis, eosinophilic, 2 11.4
46 dysphagia 11.2
47 autosomal dominant intellectual disability 30 11.1
48 extraskeletal ewing sarcoma 11.0
49 proton-pump inhibitor-responsive esophageal eosinophilia 10.7
50 barrett esophagus 10.5

Graphical network of the top 20 diseases related to Esophagitis, Eosinophilic, 1:



Diseases related to Esophagitis, Eosinophilic, 1

Symptoms & Phenotypes for Esophagitis, Eosinophilic, 1

Human phenotypes related to Esophagitis, Eosinophilic, 1:

58 31 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002015
2 edema 58 31 hallmark (90%) Very frequent (99-80%) HP:0000969
3 esophageal stricture 58 31 hallmark (90%) Very frequent (99-80%) HP:0002043
4 esophageal obstruction 58 31 hallmark (90%) Very frequent (99-80%) HP:0005240
5 gastroesophageal reflux 58 31 frequent (33%) Frequent (79-30%) HP:0002020
6 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
7 spontaneous esophageal perforation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005203
8 failure to thrive 31 HP:0001508
9 vomiting 31 HP:0002013
10 eosinophilia 31 HP:0001880
11 esophageal stenosis 58 Frequent (79-30%)
12 esophagitis 31 HP:0100633
13 abnormal esophagus morphology 58 Very frequent (99-80%)
14 abnormality of esophagus physiology 58 Occasional (29-5%)
15 epigastric pain 31 HP:0410019

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Growth Other:
failure to thrive

Abdomen Gastrointestinal:
dysphagia
vomiting
epigastric pain
difficulty feeding
food impaction
more

Clinical features from OMIM®:

610247 (Updated 20-May-2021)

UMLS symptoms related to Esophagitis, Eosinophilic, 1:


vomiting; epigastric pain

MGI Mouse Phenotypes related to Esophagitis, Eosinophilic, 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 ATP4A CCL11 CCL24 CCR3 CCR6 EPX
2 immune system MP:0005387 9.73 ATP4A CCL11 CCL24 CCR3 CCR6 EPX
3 respiratory system MP:0005388 9.23 CCL11 CCL24 CCR3 IL13 IL4 IL5

Drugs & Therapeutics for Esophagitis, Eosinophilic, 1

Drugs for Esophagitis, Eosinophilic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3 Anti-Allergic Agents Phase 4
4 Dermatologic Agents Phase 4
5 Soy Bean Phase 4
6 Cromolyn Sodium Phase 4
7 Olive Phase 4
8
Esomeprazole Approved, Investigational Phase 2, Phase 3 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
9
Reslizumab Approved, Investigational Phase 3 241473-69-8
10
Budesonide Approved Phase 3 51333-22-3 63006 5281004
11
Benralizumab Approved, Investigational Phase 2, Phase 3 1044511-01-4
12
tannic acid Approved Phase 3 1401-55-4
13
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
14 Respiratory System Agents Phase 3
15 Anti-Asthmatic Agents Phase 3
16 Hormones Phase 3
17 Anti-Inflammatory Agents Phase 3
18 Hormone Antagonists Phase 3
19 glucocorticoids Phase 3
20 Bronchodilator Agents Phase 3
21 Immunoglobulin G Phase 3
22 Immunoglobulins, Intravenous Phase 3
23 Immunoglobulins Phase 3
24 Antibodies Phase 3
25 Antibodies, Monoclonal Phase 3
26
Omalizumab Approved, Investigational Phase 2 242138-07-4
27
Losartan Approved Phase 2 114798-26-4 3961
28
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
29
Infliximab Approved Phase 2 170277-31-3
30
Loratadine Approved, Investigational Phase 2 79794-75-5 3957
31
Famotidine Approved Phase 2 76824-35-6 3325
32
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
33
Bethanechol Approved Phase 2 674-38-4 2370
34
mometasone furoate Approved, Investigational, Vet_approved Phase 2 83919-23-7
35
Trichostatin A Experimental Phase 2 58880-19-6
36 Anti-Arrhythmia Agents Phase 2
37 Angiotensin Receptor Antagonists Phase 2
38 Giapreza Phase 2
39 Angiotensinogen Phase 2
40 Angiotensin II Type 1 Receptor Blockers Phase 2
41 Antihypertensive Agents Phase 2
42 Vasoconstrictor Agents Phase 2
43 Antirheumatic Agents Phase 2
44 interferons Phase 1, Phase 2
45 Histamine H2 Antagonists Phase 2
46 Histamine H1 Antagonists, Non-Sedating Phase 2
47 Histamine Antagonists Phase 2
48
Histamine Phosphate Phase 2 51-74-1 65513
49 Histamine H1 Antagonists Phase 2
50 Neurotransmitter Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 156)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
3 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
4 Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
5 Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE) Recruiting NCT04149470 Phase 4 Omeprazole 20mg BID
6 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
7 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
8 An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002 Completed NCT00635089 Phase 3 reslizumab
9 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
10 Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
11 A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE) Completed NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
12 An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
13 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study Completed NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
14 Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial Completed NCT00266578 Phase 3 Fluticasone Propionate
15 Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial Completed NCT02778867 Phase 2, Phase 3 Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
16 Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects With Eosinophilic Esophagitis Recruiting NCT04281108 Phase 3 APT-1011;Placebo oral tablet
17 A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis Recruiting NCT04394351 Phase 3 Dupilumab;Matching Placebo
18 A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
19 A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis Recruiting NCT04322708 Phase 2, Phase 3 lirentelimab (AK002)
20 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis Recruiting NCT04543409 Phase 3
21 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Recruiting NCT04322604 Phase 3 lirentelimab (AK002)
22 Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis Active, not recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
23 A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03245840 Phase 3 Budesonide oral suspension
24 A Double-Blind, Placebo-controlled Clinical Trial to Evaluate Efficacy of Benralizumab in Subjects With Eosinophilic Gastritis Active, not recruiting NCT03473977 Phase 2, Phase 3
25 A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Enrolling by invitation NCT04620811 Phase 3 lirentelimab
26 A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Not yet recruiting NCT04753697 Phase 3 CC-93538
27 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Withdrawn NCT01702701 Phase 3 Montelukast;Fluticasone
28 Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents Completed NCT00762073 Phase 2 budesonide;placebo
29 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
30 FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis Completed NCT03191864 Phase 2 APT-1011;Placebo
31 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
32 A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE) Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
33 A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children Completed NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
34 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
35 A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
36 A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE) Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
37 Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
38 A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02379052 Phase 2 Dupilumab;Placebo
39 A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
40 A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
41 Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study Completed NCT00271349 Phase 2 Budesonide
42 A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder Completed NCT03029091 Phase 2 Losartan Potassium
43 A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. Completed NCT01808196 Phase 2 Losartan Potassium
44 A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
45 Phase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
46 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
47 A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219) Completed NCT00358449 Phase 2 mepolizumab
48 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Completed NCT03496571 Phase 2 AK002
49 A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
50 Pilot Study of Omalizumab in Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab

Search NIH Clinical Center for Esophagitis, Eosinophilic, 1

Cochrane evidence based reviews: eosinophilic esophagitis

Genetic Tests for Esophagitis, Eosinophilic, 1

Anatomical Context for Esophagitis, Eosinophilic, 1

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagitis, Eosinophilic, 1:

19
Esophagus

MalaCards organs/tissues related to Esophagitis, Eosinophilic, 1:

40
Skin, Lung, T Cells, Bone, Smooth Muscle, Small Intestine, Endothelial

Publications for Esophagitis, Eosinophilic, 1

Articles related to Esophagitis, Eosinophilic, 1:

(show top 50) (show all 2605)
# Title Authors PMID Year
1
Common variants at 5q22 associate with pediatric eosinophilic esophagitis. 57 61
20208534 2010
2
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. 61 57
16453027 2006
3
Eosinophilic esophagitis. 57 61
15329438 2004
4
A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals. 42 61
33057953 2020
5
CASE-CONTROL STUDY ON VITAMIN D STATUS IN CHILDREN AND ADOLESCENTS WITH EOSINOPHILIC ESOPHAGITIS. 42 61
33331474 2020
6
Intralesional steroid injections in addition to endoscopic dilation in benign refractory esophageal strictures : a systematic review. 42 61
33094591 2020
7
Eosinophilic esophagitis due to red yeast rice (Monacoline K) in a dietary supplement for hypercholesterolemia. 61
33386565 2021
8
A meta-analysis of efficacy of topical steroids in eosinophilic esophagitis: From the perspective of histologic, clinical, and endoscopic outcome. 61
33162187 2021
9
Immunohistochemical expression of filaggrin is decreased in proton pump inhibitor non-responders compared with proton pump inhibitor responders of eosinophilic esophagitis. 61
32909083 2021
10
A case of eosinophilic esophagitis with autoimmune polyendocrine syndrome type 2, including autoimmune gastritis. 61
33411318 2021
11
Trachealization in a Patient With Eosinophilic Esophagitis. 61
32088303 2021
12
Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension. 61
32272243 2021
13
Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis. 61
32960382 2021
14
Pediatric Patients' and Parents' Perspectives of Unsedated Transnasal Endoscopy in Eosinophilic Esophagitis: A Qualitative Descriptive Study. 61
33394888 2021
15
Eosinophilic esophagitis may persist after discontinuation of oral immunotherapy. 61
33340664 2021
16
Medication Adherence Aligns With Age and a Behavioral Checklist but Not Symptoms or Quality of Life for Patients With Eosinophilic Esophagitis. 61
33811869 2021
17
Mast cell effects on esophageal smooth muscle and their potential role in eosinophilic esophagitis and achalasia. 61
33355505 2021
18
Gene Therapy for a Murine Model of Eosinophilic Esophagitis. 61
33748982 2021
19
Dietary Management of Eosinophilic Esophagitis: Man Versus Food or Food Versus Man? 61
33518169 2021
20
Esophageal microbiome in active eosinophilic esophagitis and changes induced by different therapies. 61
33782490 2021
21
Biologics in eosinophilic esophagitis. 61
33769314 2021
22
Comorbid Diagnosis of Eosinophilic Esophagitis and Inflammatory Bowel Disease in the Pediatric Population. 61
33230079 2021
23
Patient-Reported Dysphagia in Adults with Eosinophilic Esophagitis: Translation and Validation of the Swedish Eosinophilic Esophagitis Activity Index. 61
33686463 2021
24
Image Analysis of Eosinophil Peroxidase Immunohistochemistry for Diagnosis of Eosinophilic Esophagitis. 61
32248390 2021
25
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. 61
32205221 2021
26
Assessment of IgE- and cell-mediated immunity in pediatric patients with eosinophilic esophagitis. 61
32496031 2021
27
Systemic steroids have a role in treating esophageal strictures in pediatric eosinophilic esophagitis. 61
33334703 2021
28
Dupilumab: a Review of Present Indications and Uses Out Of Indication. 61
33661102 2021
29
Esophageal Fibrosis in Eosinophilic Gastrointestinal Diseases. 61
33230074 2021
30
Lack of association of the esophageal microbiome in adults with eosinophilic esophagitis compared with non-EoE controls. 61
33723541 2021
31
Estimation of mechanical work done to open the esophagogastric junction using functional lumen imaging probe panometry. 61
33655760 2021
32
Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis. 61
32430501 2021
33
Conserved IFN Signature between Adult and Pediatric Eosinophilic Esophagitis. 61
33558373 2021
34
The role of advanced endoscopy in the management of inflammatory digestive diseases (Upper GI tract). 61
33772880 2021
35
Comorbid Occurrence of Eosinophilic Esophagitis and Inflammatory Bowel Disease. 61
32068153 2021
36
Vaping-associated esophagitis. 61
33663409 2021
37
The Evaluation of Esophageal Endoscopic Findings in Patients with Functional Esophagogastric Junction Outflow Obstruction. 61
33678743 2021
38
Endoscopic Management of Refractory Benign Esophageal Strictures. 61
33710389 2021
39
EOSINOPHILIC ESOPHAGITIS AND ACHALASIA: TWO DISTINCT NOSOLOGIC ENTITIES OR A POSSIBLE ETIOPATHOGENIC ASSOCIATION? 61
33647902 2021
40
Assessment of esophageal body peristaltic work using functional lumen imaging probe panometry. 61
33174457 2021
41
Classification of patients with esophageal eosinophilia by patterns of sensitization revealed by a diagnostic assay for multiple allergen-specific IgEs. 61
33591429 2021
42
Eosinophilic Esophagitis and IgG4: Is There a Relationship? 61
33534011 2021
43
Achalasia Is Associated With Atopy in Patients Younger Than 40 Years of Age. 61
33105192 2021
44
Food protein-induced enterocolitis syndrome epidemiology. 61
33607250 2021
45
Early life factors are associated with risk for eosinophilic esophagitis diagnosed in adulthood. 61
32766724 2021
46
Sleep in children with eosinophilic esophagitis. 61
33565029 2021
47
Effect of Maintenance Therapy for Eosinophilic Esophagitis on Need for Recurrent Dilation. 61
32166623 2021
48
A unique esophageal extracellular matrix proteome alters normal fibroblast function in severe eosinophilic esophagitis. 61
33556465 2021
49
Steroid Eluting Esophageal-Targeted Drug Delivery Devices for Treatment of Eosinophilic Esophagitis. 61
33668571 2021
50
Primary Eosinophilic Gastrointestinal Diseases Beyond Eosinophilic Esophagitis in Children. 61
32868666 2021

Variations for Esophagitis, Eosinophilic, 1

Expression for Esophagitis, Eosinophilic, 1

Search GEO for disease gene expression data for Esophagitis, Eosinophilic, 1.

Pathways for Esophagitis, Eosinophilic, 1

Pathways related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 TSLP IL5 IL4 IL13 CCR6 CCR3
2
Show member pathways
13.27 IL5 IL4 IL13 CCR6 CCR3 CCL26
3
Show member pathways
13.15 IL5 IL4 IL13 CCR6 CCR3 CCL26
4
Show member pathways
12.76 CCR6 CCR3 CCL26 CCL24 CCL11
5
Show member pathways
12.72 IL5 IL4 IL13 EPX CCL11
6
Show member pathways
12.29 TSLP IL5 IL4 IL13
7
Show member pathways
12.21 CCR3 CCL26 CCL24 CCL11
8
Show member pathways
12.19 IL5 IL4 IL13 CCL11
9
Show member pathways
12.17 CCR6 CCR3 CCL26 CCL24 CCL11
10 11.72 SIGLEC8 PTGDR2 IL5 IL4 CCR3
11 11.67 IL5 IL4 IL13
12 11.54 IL5 IL4 CCR6
13 11.5 IL5 IL4 CCL26 CCL11
14 11.29 IL5 IL4 IL13 CCL11
15 11.15 IL5 IL4 IL13 CCR3 CCL11
16 11.13 IL5 IL4 IL13
17 11.05 IL5 IL4 IL13
18 11 TSLP PTGDR2 IL5 IL4 IL13 CCR6
19 10.96 TSLP IL5 IL4 IL13
20 10.89 IL5 IL4 IL13 CCL26 CCL24 CCL11
21 10.62 IL5 IL4 IL13

GO Terms for Esophagitis, Eosinophilic, 1

Cellular components related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TSLP RNASE2 IL5 IL4 IL13 EPX
2 extracellular space GO:0005615 9.32 TSLP RNASE2 IL5 IL4 IL13 EPX

Biological processes related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.1 TSLP SIGLEC8 PTGDR2 IL5 IL4 CCR6
2 cytokine-mediated signaling pathway GO:0019221 9.93 IL5 IL4 IL13 CCL11
3 positive regulation of cell migration GO:0030335 9.88 IL4 CCL26 CCL24 CCL11
4 inflammatory response GO:0006954 9.85 IL5 IL13 CCR3 CCL26 CCL24 CCL11
5 cellular response to interferon-gamma GO:0071346 9.8 CCL26 CCL24 CCL11
6 calcium-mediated signaling GO:0019722 9.77 PTGDR2 CCR6 CCR3
7 cellular response to interleukin-1 GO:0071347 9.75 CCL26 CCL24 CCL11
8 neutrophil chemotaxis GO:0030593 9.73 CCL26 CCL24 CCL11
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 TSLP IL4 IL13
10 positive regulation of actin filament polymerization GO:0030838 9.7 CCL26 CCL24 CCL11
11 monocyte chemotaxis GO:0002548 9.69 CCL26 CCL24 CCL11
12 positive regulation of B cell proliferation GO:0030890 9.67 IL5 IL4 IL13
13 positive regulation of interleukin-10 production GO:0032733 9.65 TSLP IL4 IL13
14 lymphocyte chemotaxis GO:0048247 9.63 CCL26 CCL24 CCL11
15 sodium ion export across plasma membrane GO:0036376 9.62 ATP4A ATP12A
16 cellular potassium ion homeostasis GO:0030007 9.61 ATP4A ATP12A
17 macrophage activation GO:0042116 9.61 IL4 IL13
18 immune response GO:0006955 9.61 PTGDR2 IL5 IL4 IL13 CCR6 CCR3
19 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.6 ATP4A ATP12A
20 positive regulation of interleukin-13 production GO:0032736 9.57 TSLP IL4
21 positive regulation of endothelial cell proliferation GO:0001938 9.56 CCR3 CCL26 CCL24 CCL11
22 chemokine-mediated signaling pathway GO:0070098 9.55 CCR6 CCR3 CCL26 CCL24 CCL11
23 positive regulation of mast cell degranulation GO:0043306 9.54 IL4 IL13
24 eosinophil chemotaxis GO:0048245 9.5 CCL26 CCL24 CCL11
25 negative regulation of complement-dependent cytotoxicity GO:1903660 9.43 IL4 IL13
26 chemotaxis GO:0006935 9.17 RNASE2 PTGDR2 CCR6 CCR3 CCL26 CCL24

Molecular functions related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.54 CCL26 CCL24 CCL11
2 receptor ligand activity GO:0048018 9.5 CCL26 CCL24 CCL11
3 sodium:potassium-exchanging ATPase activity GO:0005391 9.43 ATP4A ATP12A
4 potassium-transporting ATPase activity GO:0008556 9.4 ATP4A ATP12A
5 CCR chemokine receptor binding GO:0048020 9.33 CCL26 CCL24 CCL11
6 potassium:proton exchanging ATPase activity GO:0008900 9.26 ATP4A ATP12A
7 cytokine activity GO:0005125 9.17 TSLP IL5 IL4 IL13 CCL26 CCL24
8 CCR3 chemokine receptor binding GO:0031728 9.13 CCL26 CCL24 CCL11

Sources for Esophagitis, Eosinophilic, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....